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Posttranscriptional maturation is a critical step in mi-
croRNA (miRNA) biogenesis that determines mature
miRNA levels. In addition to core components (Dro-
sha and DGCR8 [DiGeorge syndrome critical region
gene 8]) in themicroprocessor, regulatory RNA-bind-
ing proteins may confer the specificity for recruiting
and processing of individual primary miRNAs (pri-
miRNAs). Here, we identify DDX1 as a regulatory
protein that promotes the expression of a subset of
miRNAs, including five members in the microRNA-
200 (miR-200) family and four miRNAs in an eight-
miRNA signature of a mesenchymal ovarian cancer
subtype. A majority of DDX1-dependent miRNAs
are induced after DNA damage. This induction is faci-
litated by the ataxia telangiectasia mutated (ATM)-
mediated phosphorylation of DDX1. Inhibiting DDX1
promotes ovarian tumor growth and metastasis in a
syngeneic mouse model. Analysis of The Cancer
Genome Atlas (TCGA) reveals that low DDX1 levels
are associated with poor clinical outcome in patients
with serous ovarian cancer. These findings suggest
that DDX1 is a key modulator in miRNA maturation
and ovarian tumor suppression.INTRODUCTION
MicroRNAs (miRNAs) are small endogenous noncoding RNAs
that regulate gene expression by repressing translation and/or
promoting degradation of their target mRNAs. Universally ex-
pressed in nearly all metazoans, plants, and even DNA viruses,
they are involved in many cellular processes such as prolifera-
tion, differentiation, stress responses, apoptosis, and develop-
ment (Bartel, 2009; Siomi and Siomi, 2010). The biogenesis of
miRNA is a tightly regulated multistep process. In the nucleus,Cell Reprimary miRNAs (pri-miRNAs) are first processed by the micro-
processor containing the ribonuclease (RNase) III enzyme Dro-
sha and its cofactor DGCR8 (DiGeorge syndrome critical region
gene 8) (Gregory et al., 2006). The processed products are pre-
cursormiRNAs (pre-miRNAs) that have a hairpin structure of70
nt. They are exported by exportin 5 to the cytoplasm (Murchison
and Hannon, 2004), where the stem loops of pre-miRNAs are
cleaved off by another RNase III, Dicer, resulting in the produc-
tion of mature miRNAs (Lund and Dahlberg, 2006). The RNA-
induced silencing complex (RISC) loaded with mature miRNA
is subsequently guided by miRNA to pair with target mRNA tran-
scripts at their 30 UTR and induce mRNA degradation or inhibi-
tion of translation (Chong et al., 2010; Friedman et al., 2009).
Aberrant miRNA expression has been reported in a variety of
human cancers (Iorio and Croce, 2012; Esteller, 2011). The first
direct evidence was derived from studies for identification of
tumor suppressor genes at chromosome 13q14 in chronic lym-
phocytic leukemia (CLL) (Calin et al., 2002, 2005). Deletion of mi-
croRNA-15a (miR-15a) and miR-16-1 in the 13q14 region was
found to be involved in the pathogenesis of human CLL. Since
then, accumulating evidence has shown that many miRNA
genes residing in the regions of chromosomal instability or
nearby chromosomal breakpoints are prone to genomic alter-
ations (Calin et al., 2004; Zhang et al., 2006). In addition to
genomic abnormalities in the miRNA genes, defects in miRNA
biogenesis machinery often result in miRNA dysregulation in
human cancer, which include DNA/histone modifications, tran-
scriptional activation/suppression, and pri-miRNA maturation
(Wan et al., 2014). In particular, posttranscriptional maturation,
rather than transcriptional regulation, determines the levels of
mature miRNAs in many cases. Suppression of global miRNA
production was found in many types of human cancer due to
downregulated expression of Drosha or Dicer (Davalos and Es-
teller, 2010; Merritt et al., 2008). However, human cancer miR-
Nome studies have demonstrated aberrant expression of many
individual miRNAs (oncogenic microRNAs or tumor-suppressive
miRs) (Lee and Dutta, 2009), which obviously cannot be ascribed
to a global shutdown of the miRNA-processing machinery. It
appears that regulatory components in the Drosha and Dicerports 8, 1447–1460, September 11, 2014 ª2014 The Authors 1447
complexes may confer miRNA specificity by controlling their
processing activity in sequence- or structure-specific manners
(Zhang and Lu, 2011). Several RNA-binding proteins, such as
KSRP, TDP-43, p68, and p72, have been identified as such reg-
ulatory proteins that interact with miRNA-processing complexes
and modulate maturation of specific miRNAs (Fuller-Pace and
Moore, 2011; Kawahara and Mieda-Sato, 2012; Trabucchi
et al., 2009; Mori et al., 2014).
Among all cancer-associated miRNAs, the miR-200 family
(miR-200a/miR-200b/miR-200c, miR-141, and miR-429) is
believed to play an essential role in tumor suppression by inhib-
iting epithelial-mesenchymal transition (EMT), an initiating step
of metastasis (Gregory et al., 2008; Korpal et al., 2008; Park
et al., 2008). The miR-200 members target the E-cadherin tran-
scriptional repressors ZEB1 and ZEB2 (Korpal et al., 2008; Kor-
pal and Kang, 2008). Knockdown of miR-141 and miR-200b was
shown to reduce E-cadherin expression and thus increase cell
motility and induce EMT (Pecot et al., 2013). Forced miR-200
expression inhibited the formation of distant metastasis in lung
adenocarcinoma (Yang et al., 2011). However, miR-200 overex-
pression promoted metastatic colonization in mouse models
probably through direct targeting of Sec23a (Korpal et al.,
2011). The seemingly conflicting reports suggest the role of
miR-200 members in suppressing or promoting metastasis in
cancer-dependent contexts. Our recent study demonstrated
that in ovarian, lung, renal, and basal-like breast adenocarci-
nomas, elevatedmiR-200 expression portends improved clinical
outcome, in part, through secretion of metastasis-suppressive
proteins (Pecot et al., 2013). We recently identified amiRNA-reg-
ulatory network that defines a mesenchymal subtype associated
with poor overall survival in patients with serous ovarian cancer
(Yang et al., 2013). Two miR-200 family members, miR-200a
and miR-141, are included in this miRNA signature, supporting
the role of miR-200 members in EMT and cancer metastasis.
Equally as important as transcriptional regulation, the pro-
cessing of premature miRNAs (pri-miRNAs and pre-miRNAs) is
a critical rate-limiting step that controls mature miRNA levels.
The first step in miRNA maturation is executed by the Drosha
microprocessor in which Drosha and DGCR8 are the core com-
ponents (Gregory et al., 2004; Lee et al., 2003). However, neither
Drosha nor DGCR8 has binding specificity for individual pri-
miRNAs. Differential expression levels of mature miRNAs, even
those derived from the same primary transcript, suggest that
regulatory components in the complexmay confer the specificity
for recruiting and processing pri-miRNAs. Among a growing list
of RNA-binding proteins identified from the microprocessor
complex are the members of the DEAD box helicase family,
including p68, p72, and DDX1 (Gregory et al., 2004; Mori et al.,
2014; Suzuki et al., 2009). In the present study, we show that
DDX1 interacts with the Drosha complex and promotes the
expression of a subset of miRNAs.
RESULTS
DDX1 Interacts with the Drosha Microprocessor
DDX1 was first identified in a high-molecular mass complex con-
taining a number of Drosha-associated polypeptides (Gregory
et al., 2004). However, the functional role of DDX1 has yet to1448 Cell Reports 8, 1447–1460, September 11, 2014 ª2014 The Aube known. A majority of DDX1 is present in the cell nucleus,
and significant colocalization between DDX1 and Drosha was
observed (Figure S1A). We determined the physical interaction
of DDX1 with the Drosha microprocessor (Figure 1A). Endoge-
nous DDX1 was detected in the Drosha immunoprecipitate,
and conversely, Drosha and DGCR8 were also identified in the
DDX1 immunoprecipitate. Two negative control RNA-binding
proteins, ADAR and p84, were not detected in the Drosha com-
plex (Figure 1A) (Kawahara andMieda-Sato, 2012). To determine
whether RNA molecules are involved in these interactions, the
DDX1 immunoprecipitates were treated with RNase A (degrad-
ing single-stranded RNA) (Raines, 1998) or RNase V1 (degrading
double-stranded RNA) (Kawai and Amano, 2012) to remove
RNAs (Figure S1B). Regardless of RNase treatments, Drosha
firmly interacted with endogenous DDX1 on the DDX1 anti-
body-conjugated beads, and no Drosha was dissociated and
released to the supernatant (Figure 1B). Therefore, the DDX1-
Drosha interaction does not involve any RNA molecules. To
determine the domain(s) of DDX1 responsible for the Drosha
binding, full-length DDX1 or its deletion mutants were tested in
the glutathione S-transferase (GST) pull-down assay (Figure 1C).
The C-terminal sequence (amino acid residues 460–740),
including a helicase domain (residues 493–681), was essential
for DDX1 to interact with Drosha, whereas most of DDX1 (resi-
dues 1–460) at the N terminus was dispensable.
DDX1 Promotes the Expression of a Subset of miRNAs
Observation of direct interaction between DDX1 and the micro-
processor led us to investigate a potential role of DDX1 in miRNA
biogenesis. Using a quantitative RT-PCR (qRT-PCR) human
miRNA array, miRNA expression profiles in control and DDX1-
knockdown U2OS cells were analyzed to determine the effect
of DDX1 on global miRNA expression (Figure 1D). Depletion of
DDX1 significantly decreased the expression levels of a subset
of 36 miRNAs (cutoff >2-fold) (Gene Expression Omnibus
[GEO] accession number GSE54990), including all 5 members
in the miR-200 family (miR-200a, miR-200b, miR-200c, miR-
141, andmiR-429). Our recent study of ovarian cancer genomics
revealed an eight-miRNA signature that defines a mesenchymal
subtype of serous ovarian cancer (Yang et al., 2013). Among the
eight miRNAs, four miRNAs (miR-200a, miR-29c, miR-141, and
miR-101) are significantly dependent on DDX1, suggesting that
DDX1may play a role in ovarian tumor progression. To determine
whether DDX1 regulates themiRNA expression at transcriptional
or posttranscriptional levels, we performed nuclear run-on as-
says to measure the effect of DDX1 on pri-miRNA transcription.
No notable differences were seen in the transcription of pri-
miR-200 members from the two miR-200 gene clusters (miR-
200a/miR-200b/miR-429 and miR-200c/miR-141) in the control
and DDX1-silenced cells (Figure S2A). However, levels of mature
DDX1-dependent miRNAs, but not control miR-21, were signifi-
cantly decreased in the DDX1-knockdown U2OS cells (Figures
2A and S2B). Due to the potential inhibition of miRNA-
processing activity, primary transcripts of the DDX1-dependent
miRNAswere accumulated. Conversely, these DDX1-dependent
miRNAs were upregulated in the DDX1-overexpressing cells
(Figure 2B). These results suggest that DDX1 promotes the
expression of specific miRNAs at the posttranscriptional level.thors
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Figure 1. Interaction of DDX1 with the
Drosha Microprocessor
(A) Interaction between endogenous DDX1 and
Drosha/DGCR8. Immunoprecipitation (IP) and
western blotting analyses were performed using
indicated antibodies. Normal immunoglobulin G
(IgG) was used as a negative control for IP. RNA-
binding proteins ADAR and p84 were used as
negative controls for the Drosha-binding proteins.
WCL, whole-cell lysate.
(B) RNA-independent interaction between DDX1
and Drosha. DDX1 immunoprecipitates were
treated with RNase A (10 U) or RNase V1 (10 U) and
separated to supernatant and bead-bound frac-
tions for western blotting analyses.
(C) Schematic representation of DDX1 domains
(upper panel) and the interaction between Drosha
and truncated forms of DDX1 (bottom panel). GST-
fused DDX1 proteins were immobilized on gluta-
thione Sepharose beads and mixed with the lysate
of HEK293T cells expressing Drosha-FLAG.
(D) Depletion of DDX1 inhibits the expression of a
subset of miRNAs. Total RNAs from control and
DDX1 knockdown (KD) were subject to global
miRNA-profiling analyses using qPCR miRNA mi-
croarray. Green and red on the heatmap indicate a
decrease and increase of miRNA level, respec-
tively, and color intensities correspond to relative
signal levels. A total of 36 miRNAs with over 2-fold
reduction in the DDX1-knockdown cells were
identified as DDX1-dependent miRNAs. The
DDX1-dependent miRNAs in the miR-200 family
and the eight-miRNA signature for the mesen-
chymal subtype of ovarian cancer are marked with
an asterisk (*).
See also Figure S1.We next examined the effect of DDX1 knockdown on miRNA
expression in three ovarian cancer cell lines (HeyA8, SKOV3,
and IG10) and a pair of isogenic HCT116 cell lines
(HCT116p53+/+ and HCT116p53/) (Figure 2C). DDX1 was
efficiently knocked down in all the tested cell lines (Figure S2B).
Levels of the DDX1-dependent miRNAs were measured by
quantitative PCR (qPCR) using specific primers for mature miR-
NAs. Despite some variations across cell lines, the DDX1-
dependent miRNAs were consistently suppressed in the
DDX1-silenced cells (Figures 2C, S2C, and S2D). As a control,
miR-21 levels were not influenced by the DDX1 knockdown.
The level of mature miR-429 could not be determined due to
low expression levels (high cycle threshold values in qPCR) in
most of the tested cell lines (Figure S2C). Although p53 was
previously reported to transcriptionally activate miR-200 genes
(Kim et al., 2011; Chang et al., 2011), our results from
HCT116p53+/+ and HCT116p53/ cells suggest that DDX1
regulates miRNA expression in a p53-independent manner
(Figure 2C).Cell Reports 8, 1447–1460, SepDDX1 Directly Binds Specific
Pri-miRNAs and Promotes Their
Processing
As a double-stranded RNA-binding pro-
tein, DDX1 may specifically bind targetpri-miRNAs and recruit them to the microprocessor. RNA im-
munoprecipitation (RIP) assays showed specific interactions
between endogenous DDX1 and five of the DDX1-dependent
pri-miRNAs (Figures 3A, S3A, and S3B). As a DDX1-independent
negative control, pri-miR-21 had no interaction with DDX1. To
further confirm the pri-miRNA-DDX1 interaction, we employed
a MS2-TRAP (MS2-tagged RNA affinity purification) assay
(Yoon et al., 2012). In this assay, MS2 is a 19 nt bacteriophage
RNA sequence that folds into a hairpin loop structure, which is
recognizedwith high specificity and affinity by the bacteriophage
capsid protein MS2P (Figure 3B). MS2-tagged pri-miR-200a/pri-
miR-200bwas coexpressedwithGST-MS2P in the cells. The pri-
mRNA-protein complex was pulled down by anti-GST beads
(Figure S3C). Both DDX1 and Drosha were detected in the pri-
miR-200a/pri-miR-200b immunoprecipitates. However, only
Drosha, but not DDX1, was detected in the control pri-miR-21
immunoprecipitates (Figure 3B). Because DDX1 directly inter-
acts with pri-miRNAs and its association with the Drosha com-
plex is independent of RNA (Figure 1B), we postulated thattember 11, 2014 ª2014 The Authors 1449
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Figure 2. Posttranscriptional Regulation of miRNA Expression by DDX1
(A) Levels of primary or mature forms of the DDX1-dependent miRNAs in control and DDX1-knockdown U2OS cells.
(B) Levels of primary or mature forms of the DDX1-dependent miRNAs in control and DDX1-overexpressing U2OS cells. In both (A) and (B), miR-21 was used as a
DDX1-independent control.
(C) Levels of DDX1-dependent miRNAs in control or DDX1-knockdown cell lines as indicated. HeyA8 and SKOV3 are human ovarian cancer cell lines, and IG10 is
amouse ovarian cancer cell line. HCT116p53+/+ and HCT116p53/ are a pair of isogenic colorectal cancer cell lines. U6RNAwas used for normalization in qPCR
analyses, and miR-21 was used as a DDX1-independent miRNA control.
Error bars represent the mean ± SD: *p < 0.05; **p < 0.001. See also Figure S2.DDX1may enhance the recruitment of specific pri-miRNAs to the
Drosha microprocessor. In the Drosha RIP assay, depletion of
DDX1 specifically decreased the amounts of pri-miR-200a/pri-1450 Cell Reports 8, 1447–1460, September 11, 2014 ª2014 The AumiR-200b, but not pri-miR-21 (negative control), in the Drosha
complex (Figure 3C). To determine the effect of DDX1 on the
pri-miRNA processing, we conducted a luciferase-based in vivothors
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Figure 3. DDX1 Recruits Target Pri-miRNAs to the Drosha Microprocessor and Promotes Their Processing
(A) RIP analysis reveals that primary forms of DDX1-dependent miRNAs are physically associated with DDX1 in U2OS cells. The DDX1-bound pri-miRNAs were
analyzed by qRT-PCR. Control IgG was used as a negative control (*p < 0.05; **p < 0.01).
(B) Interaction between pri-miRNAs and DDX1 determined by the MS2-TRAP assay. Schematic illustration of MS2-TRAP assay is shown at the top. MS2-tagged
pri-miRNAs and their associated protein complexes were pulled down by anti-GST beads, and proteins were detected by western blotting.
(C) RIP analysis of the Drosha-interacting pri-miRNAs in control and DDX1-knockdown cells (**p < 0.01). Pri-miR-21 was used as a DDX1-independent control.
(D and E) Pri-miRNA-processing activity in DDX1-knockdown (D) and -overexpressing (E) cells. The firefly luciferase signals are normalized by internal control
Renilla luciferase readings, and relative processing activity was shown as fold changes (**p < 0.01).
Error bars represent the mean ± SD in this figure. See also Figures S3 and S4.pri-miRNA-processing assay (Kawai and Amano, 2012). Human
U2OS cells were transfected with luciferase vectors carrying
a pri-miRNA sequence between the open reading frame of lucif-
erase and polyadenylation signal. The Drosha-mediated cleav-
age of pri-miRNA results in loss of the polyadenylation tail,
leading to instability of the luciferase transcript and decreased
luciferase signals (Figure S3D). In the functionality test for theCell Reassay, the Drosha-processing activity on each pri-miRNA was
inversely correlated with the luciferase activity (Figure S3E). We
assessed the processing activity of each pri-miRNA in the con-
trol, DDX1-overexpressing, and DDX1-knockdown cells (Figures
3D and 3E). Overexpression of DDX1 significantly increased
the Drosha-mediated processing activities on pri-miR-200a/
pri-miR-200b. By contrast, knockdown of DDX1 inhibited theports 8, 1447–1460, September 11, 2014 ª2014 The Authors 1451
processing of pri-miR-200a/pri-miR-200b. As negative controls,
the processing of pri-miR-16 and pri-miR-145 was not affected
by altered DDX1 expression. These results suggest that DDX1
facilitates the Drosha-mediated pri-miRNA processing.
To understand sequential and structural requirements of pri-
miRNAs for their interaction with DDX1, we analyzed the pre-
dicted secondary structures of theDDX1-dependent pri-miRNAs.
We found two conserved residues, AA, near or in the loops of
these pre-miRNAs (Table S1; Figure S4A). Mutating the AA dinu-
cleotide to CC abolished the interaction between pri-miR-200a/
pri-miR-200b and DDX1 (Figure S4B), suggesting that the AA
dinucleotide is probably essential for the DDX1 interaction.
DDX1 Promotes Pri-miRNA Processing in DNA
Damage Response
Recent studies have shown that DNA damage stress leads to a
global change of miRNA expression profiles (Pothof et al.,
2009; Wan et al., 2013; Zhang et al., 2011; Ishii and Saito,
2006). Interestingly, a previous report showed that DDX1 was
colocalized with ionizing radiation-induced DNA damage foci
(Li et al., 2008). We attempted to determine whether DDX1
serves as a mediator that translates DNA damage signaling to
miRNA biogenesis. DDX1 was primarily in the nucleus and trans-
localized into the DNA damage foci (indicated by g-H2AX stain-
ing) after treatment with neocarzinostatin (NCS), a radiomimetic
drug (Figure 4A). We analyzed global miRNA expression profiles
in control and stable DDX1-knockdown U2OS cells treated
with NCS, and identified DDX1-dependent and DNA damage-
induced miRNA signatures (Figure 4B). Interestingly, a majority
of the DDX1-dependent miRNAs (31 out of 35) were significantly
induced after DNA damage (Figures 4B and 4C), indicating the
DNA damage-induced DDX1 activity in miRNA biogenesis.
Consistent with the global miRNA expression data, levels of
maturemiR-200a/miR-200b/miR-200c were gradually increased
after DNA damage (Figures 4D and S5A). However, knockdown
of DDX1 severely suppressed their basal expression levels and
abolished their induction after DNA damage. Our previous study
showed that miR-21 is induced by phosphorylated KSRP after
DNA damage (Zhang et al., 2011). Indeed, miR-21 was ex-
pressed and induced in a DDX1-independent manner (Fig-
ure 4D). The negative control miR-218 was not affected by
DDX1 and DNA damage stress. Induction of miR-200 members
after DNA damage was independent of p53 status in the isogenic
p53+/+ and p53/ HCT116 cell lines (Figure S5B), but depletion
of DDX1 or inhibiting ataxia telangiectasia mutated (ATM) activity
completely abolished the DNA damage-mediated induction of
miR-200 members (Figures S5C and S5D). Although p53 was
previously shown to transactivate miR-200 genes (Chang et al.,
2011; Kim et al., 2011), our results suggest that DDX1-depen-
dent posttranscriptional regulation is essential to determine
miR-200 expression levels.
ATM Phosphorylation Facilitates DDX1 in the Pri-
miRNA Processing
DDX1 is recruited to the DNA damage foci possibly via its inter-
action with RAD50 and ATM (Li et al., 2008). However, the levels
of DDX1 and its interactions with those proteins in the DNA dam-
age foci were not notably changed after DNA damage (Figures1452 Cell Reports 8, 1447–1460, September 11, 2014 ª2014 The AuS6A and S6B), suggesting that DDX1 may not be essential for
the initiation of DNA damage response. Actually, only minimal
changes in the activity of homologous recombination DNA repair
were observed in the DDX1-overexpressing or -knockdown cells
(Figure S6C). Consistent with the previous report by Li et al.
(2008), we confirmed that DDX1 is phosphorylated in an ATM-
dependent manner (Figure S6D, upper panel). In silico analysis
identified two consensus ATM phosphorylation sites on DDX1
in mammals (Figure 5A). We generated a phosphorylation-defi-
cient mutant (S373A/S667A, shown as 2MT) of DDX1. In vitro
and in vivo ATM kinase assays showed that this mutant DDX1
could not be phosphorylated by ATM (Figure 5B and the bottom
panel of Figure S6D). We postulated that ATM-mediated phos-
phorylation of DDX1 may facilitate DDX1 in the pri-miRNA pro-
cessing. We first investigated the physical interaction between
DDX1 and Drosha in the presence or absence of DNA damage.
No differences were observed on the protein levels of DDX1
and Drosha and their nuclear/cytoplasmic distributions after
DNA damage (Figures S6E–S6G), and their interaction was not
significantly changed as well (Figure 5C). These results suggest
that phosphorylation of DDX1 does not enhance its interaction
with theDroshamicroprocessor. Next, we performedRIP assays
to determine whether the pri-miRNA-binding activity of DDX1
was enhanced after DNA damage. Markedly increased levels
of pri-miR-200a/pri-miR-200b were bound by DDX1 after DNA
damage (Figure 5D). As a result, the levels of mature miR-
200a/miR-200b were increased after DNA damage, and this
induction was abolished by inhibition of ATM (Figure 5E), sug-
gesting that the ATM phosphorylation promotes DDX1 to more
efficiently recruit pri-miRNAs to the Drosha complex. Next, we
examined whether expression of wild-type (WT) or phosphoryla-
tion-deficient (2MT) DDX1 restored the DNA damage-induced
miR-200a/miR-200b biogenesis in the DDX1-depleted cells.
We generated small hairpin RNA (shRNA)-resistant DDX1
expression constructs (WT and mutant) by mutating shRNA-tar-
geting nucleotides to synonymous ones. Overexpression of WT
DDX1 restored the expression of mature miR-200a/miR-200b,
and DNA damage further induced the levels of these miRNAs
(Figure 5F). By contrast, the phospho-mutant DDX1 failed to
induce miR-200a/miR-200b levels after NCS treatment (Fig-
ure 5F). However, this phospho-mutant form was capable of
restoring basal levels of miR-200a/miR-200b in the DDX1-
depleted cells. This result is consistent with the observation
showing that DDX1’s interaction with the Drosha micropro-
cessor is independent of DNA damage stress (Figure 5C). In un-
stressed cells, the phospho-mutant DDX1 interacts with the
Drosha complex and maintains its basic function in pri-miRNA
processing. However, the ATM phosphorylation enhances
DDX1’s interaction with target pri-miRNAs and thus induces their
processing after DNA damage.
DDX1 Inhibits Ovarian Tumor Invasion and Metastasis
We recently showed that elevated miR-200 expression is asso-
ciated with good clinical outcomes in ovarian, renal, and lung
cancers (Pecot et al., 2013). Moreover, our study of ovarian can-
cer genomics revealed an eight-miRNA signature that defines a
mesenchymal subtype of serous ovarian cancer (Yang et al.,
2013). The DDX1-dependent miRNAs include not only all of thethors
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five members in the miR-200 family but also four miRNAs (miR-
200a, miR-29c, miR-141, and miR-101) in the eight-miRNA
signature, suggesting that DDX1 may be a key player in ovarian
tumor progression. We first examined the effect of DDX1 on
ovarian cancer cell invasion. Results of in vitro invasion assays
demonstrated that ovarian cancer cells SKOV3 (human) and
IG10 (mouse) had much higher activity of cell invasion when
DDX1was knocked down (Figure 6A), although their proliferation
rates were not notably affected (data not shown). Next, we em-
ployed a syngeneic ovarian tumor model to examine the role of
DDX1 on ovarian tumor progression in vivo. DDX1 was stably
knocked down in the murine IG10 cells, which are transformed
ovarian surface epithelial cells derived from C57BL/6 mice
(Roby et al., 2000). The IG10 cells stably expressing luciferase
were generated for monitoring tumor growth in vivo. Control
and DDX1-silenced IG10 cells (1 3 106) were injected into the
peritoneal cavity of C57BL/6N mice (n = 10 per group). Tumor
growth within the peritoneal cavity and buildup ascites were
monitored. We observed dramatic increases of luminescence
in the mice bearing tumors derived from the DDX1-silenced cells
(Figure 6B). After 8 weeks, the animals were sacrificed and in-
spected for tumor weights and tumor nodules. Depletion of
DDX1 resulted in profound increases in tumor weight (161.6% in-
crease; p < 0.001) and number of nodules (188.2% increase; p <
0.001) (Figure 6C). Moreover, higher metastatic activity of the
DDX1-silenced ovarian tumors was observed. These tumors
showed highly frequent metastases to common metastatic sites
(mesentery, omentum, diaphragm, perihepatic sites, pelvic and
paraaortic lymph nodes, and kidney) of high-grade serous
ovarian carcinoma (Figures 6D and 6E). In the DDX1-silenced tu-
mors, the levels of miR-200a/miR-200b were significantly
decreased, whereas their targets ZEB1 and ZEB2 were induced
(Figure 6F). To assess whether knockdown of DDX1 promotes
EMT in vivo, we measured the levels of ZEB1, E-cadherin, and
Vimentin in control and DDX1-silenced tumors. In comparison
with the control, the DDX1-silenced tumors exhibited elevated
levels of ZEB1 (145% increase; p = 0.017) and Vimentin (150%
increase; p = 0.011) and decreased levels of E-cadherin (61%
reduction; p = 0.009) (Figure 6G). Taken together, these results
suggest that suppression of DDX1 promotes ovarian tumor
progression.
The Potential of DDX1 as a Predictive Marker of
Clinical Outcome
To determine the correlation between DDX1 levels and clinical
outcome of patients with cancer, we analyzed the expression
of DDX1 and miRNAs and the correlation between DDX1 and
overall patient survival in The Cancer Genome Atlas (TCGA).
We randomly split the entire population of patients with certain
types of cancer into training/validation cohorts. Analysis of
both cohorts across cancer types revealed that low levels of
DDX1 are significantly associated with poor overall survival in
patients with serous ovarian adenocarcinoma and in patients
with kidney renal clear cell carcinoma (Figures 7A, 7B, S7A,
and S7B). In the validation cohort of ovarian adenocarcinomas,
the median survival of patients with high-DDX1 ovarian cancer
is 70.8 months, which is remarkably better than 38.4 months
for patients with low-DDX1 ovarian cancer (p = 0.01075) (Fig-Cell Reure 7A). Levels of miR-200a and miR-200c in DDX1-high ovarian
tumors are 2.1-fold (p = 0.006) and 1.8-fold (p = 0.04) higher than
those in DDX1-low tumors, respectively, in the validation data set
(Figure 7C). The positive correlation between DDX1 andmiR-200
levels was also observed in the training set (Figure S7C). Consis-
tent with TCGA data analysis, we observed that DDX1 levels
were positively correlated with miR-200a levels from in situ hy-
bridization analyses of ovarian tumor tissue microarray (Figures
7D and S7D). These results suggest that DDX1 is potentially a
predictive marker for clinical outcome of patients with ovarian
cancer.
DISCUSSION
The current study identifies DDX1 as a cofactor in the Drosha
microprocessor, which governs posttranscriptional maturation
of a subset of miRNAs. Drosha is an RNase III enzyme that binds
and cleaves double-stranded RNA with no sequence specificity.
A recent study showed that 1 nt change in stem loop of pri-
miRNA inhibits the Drosha-mediated cleavage, suggesting that
the stem-loop structure of pri-miRNA may be critical for the Dro-
sha activity (Slezak-Prochazka et al., 2010). Although all the pri-
miRNAs share this common feature with one or more stem-loop
structures, each pri-miRNA also has unique complexity in
sequence and structure that may determine the specificity of
the Drosha-mediated processing. Those RNA-binding proteins,
such as DDX1, become perfect candidates to provide this type
of specificity through their selective interaction with target pri-
miRNAs. Moreover, in contrast to another RNase III endonu-
clease (Dicer) for pre-miRNA processing, Drosha does not
have helicase activity (Welker et al., 2011). Interaction of DDX1
with the Drosha microprocessor may not only confer pri-
miRNA-binding specificity but also help resolve the complex
structure of pri-miRNA to generate desirable stem-loop structure
for efficient cleavage.
The key player in the DNA damage response, p53, is also
involved in the regulation of miRNA expression. Whereas it is a
defined transcriptional factor that transactivates miR-34, miR-
192, and miR-215 (He et al., 2007; Braun et al., 2008), p53 also
upregulates the posttranscriptional processing of miR-16, miR-
143, and miR-145 through association with p68 in the Drosha
complex (Suzuki et al., 2009). In addition, p53 suppresses EMT
by repressing the expression of ZEB1 and ZEB2 through direct
transactivation of miR-200 genes in primary hepatocellular carci-
nomas and human mammary epithelial cells (Kim et al., 2011;
Chang et al., 2011). In the current study, we found that most of
the DDX1-dependent miRNAs are induced after DNA damage,
but they are not associated with p53 (Figure 1D), suggesting
that DDX1 regulates miRNA biogenesis in a p53-independent
manner. Regardless of p53 status, DDX1-dependent induction
of miR-200 members was observed in the isogenic p53+/+ and
p53/ HCT116 cell lines. However, the p53-induced miR-200
expression is completely dependent on DDX1 (Figure S5C).
Thus, the ATM kinase not only induces the level of p53 but also
phosphorylates DDX1 and facilitates the processing of pri-miR-
NAs in theDNAdamage response. Our analysis of the ovarian se-
rous adenocarcinoma database in TCGA revealed that a majority
(90.7% or 573 out of 632) of ovarian tumors possess mutant p53,ports 8, 1447–1460, September 11, 2014 ª2014 The Authors 1455
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indicating that DDX1-associated, but not p53-associated, mech-
anism may determine the miR-200 expression in ovarian cancer
cells. We propose that the ATM-initiated DNA damage signaling
promotes the expression of a subset of miRNAs and inhibits
tumor cell invasion in a DDX1- and p53-dependent manner.
However, tumor progression is often accompanied by inactiva-
tion of DNAdamage response and p53 (Bartkova et al., 2006;Ha-
lazonetis et al., 2008). The protein level of DDX1 will determine
the expression of miR-200 members in those malignant tumor
cells during invasion and metastasis.
We recently identified an eight-miRNA signature for the
mesenchymal subtype of serous ovarian cancer. Interestingly,
four (miR-200a, miR-101, miR-141, andmiR-29c) out of the eight
miRNAs in this signature are positively regulated by DDX1, sug-
gesting that low levels of DDX1 may predict for high metastasis
potential of human ovarian cancer. Indeed, analysis of TCGA
database revealed that low levels of DDX1 are significantly asso-
ciated with poor clinical outcomes in patients with serous
ovarian cancer. Depletion of DDX1 significantly promotes
ovarian tumor metastasis in a mouse syngeneic ovarian tumor
model. Although lower levels of DDX1 are correlated with poor
clinical outcome in patients with ovarian tumors, it is unknown
whether the function of DDX1 in tumor progression is completely
mediated by miRNAs. As an RNA-binding protein with RNA heli-
case activity, DDX1 may regulate the stability and expression of
many types of RNA molecules such as mRNA and noncoding
RNAs. Identification of the DDX1-assoicated RNAs and analysis
of these RNA structures will allow us to better understand biolog-
ical functions of DDX1. In addition, it is also of great importance
to define how DDX1 expression is regulated in normal and can-
cer cells. Transcriptional and posttranscriptional mechanisms
need to be identified to interpret the suppressed expression of
DDX1 in cancer cells. It will also be of great interest to determine
whether other cellular stresses in tumors, such as hypoxia or
reactive oxygen species, contribute to the activity of DDX1.
Further studies of DDX1-dependent miRNAs will identify molec-
ular interactions between DDX1, miRNAs and cancer signaling
pathways.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
U2OS and human embryonic kidney 293T (HEK293T) cell lines were pur-
chased from the American Type Culture Collection, and HCT116p53+/+ andFigure 6. Silencing DDX1 Promotes Ovarian Tumor Cell Invasion In Vit
(A) Knockdown of DDX1 promotes ovarian tumor cell invasion. Matrigel invasion a
The average number of invasive cells per field of view (FOV) is presented (**p < 0
(B) Knockdown of DDX1 promotes IG10 syngeneic tumor growth. Control and
peritoneally into female C57BL/6N mice. Shown are the representative luciferase
(C) Quantification of tumor weights and tumor nodules in mice (n = 10 for each g
(D) Representative images of tumor nodules and metastases in the mice carryin
cells. Shown here are tumor mass in omentum of a control tumor (I) and tumor m
diaphragm (VI) of DDX1-knockdown tumors.
(E) Frequency of metastases to distant sites (mesentery, omentum, diaphragm, pe
and ovary.
(F) Levels of miR-200a/miR-200b and their targets ZEB1 and ZEB2 in control an
(G) Immunohistochemical (IHC) analysis of ZEB1, E-Cadherin, and Vimentin in con
ZEB1, E-Cadherin, and Vimentin are shown in the graph (see Experimental Pro
hematoxylin and eosin staining.
Cell ReHCT116p53/were obtained from B. Vogelstein at Johns Hopkins University.
These cell lines were maintained in Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum (FBS) at 37C in 5% CO2. HeyA8, SKOV3, and IG10
cell lines were grown in RPMI medium with 15% FBS at 37C in 5% CO2. To
induce double-stranded DNA breaks, cells were treated with NCS (#N9162;
Sigma-Aldrich) at indicated concentrations and harvested at indicated time
points after treatment for RNA and protein analyses. To inhibit ATM kinase ac-
tivity, cells were treated with 10 mM ATM kinase inhibitor CGK733 (#118501;
Calbiochem) or DMSO (mock treatment) 1 hr prior to DNA-damaging
treatment.
Syngeneic Ovarian Tumor Mouse Model
Female C57BL/6N mice (6–8 weeks old) were purchased from Jackson
Laboratory. All studies were approved and supervised by the Institutional
Animal Care and Use Committee at the MD Anderson Cancer Center. After
mice were anesthetized, control and DDX1-silenced murine IG10-luciferase
cells (1 3 106) in 100 ml Hank’s balanced salt solution were intraperitoneally
injected. Tumors were monitored by the IVIS imaging system (PerkinElmer)
after luciferin injection for 10 min. Mice were euthanized before they met
the institutional euthanasia criteria for tumor burden and overall health
condition.
Nuclear Run-On Assay
Nuclear run-on assay was performed as described previously (Wan et al.,
2013). Briefly, an aliquot (1 mg) of single-stranded DNA fragment (complemen-
tary to each specific miRNA transcript) was amplified by PCR. DNA was plot
blotted onto 0.45 mm nitrocellulose membrane (Bio-Rad). After isolation of
the nucleus and run-on transcription reaction, RNAwas isolatedwith TRIzol re-
agent. Membraneswere probedwith 32P-labeled run-onRNA, exposed to film,
and analyzed for intensity with a scintillation counter.
MS2-TRAP Assay
The MS2-TRAP assay was performed as described previously by Yoon
et al. (2012). In brief, vectors expressing MS2P-GST and MS2-tagged pri-
miRNA were transfected into HEK293T cells. Cells were lysed, and the
RNA-protein complexes were affinity purified using GST agarose beads.
Pri-miRNAs in the complexes were isolated and detected by qRT-PCR,
and the RNA-binding proteins (DDX1 and Drosha) were detected by western
blotting analysis.
In Vivo Pri-miRNA-Processing Assay
In vivo pri-miRNA processing was performed as previously described by Ka-
wai and Amano (2012). Briefly, pmirGLO-miR-200a, miR-200b, miR-16, or
miR-145 expression vectors were transfected into HEK29T cells. After 48 hr,
cell extracts were prepared, and the ratios of firefly and Renilla luciferase
were obtained using a Dual-Luciferase Reporter Assay kit (Promega). As a
control, empty pmirGLO vector was used. Relative pri-miRNA-processing
activity is calculated as (Lucno-insert  Lucpri-insert)/Lucpri-insert. Lucno-insert and
Lucpri-insert numbers were normalized with Renilla luciferase numbers.ro and Ovarian Tumor Progression In Vivo
ssays were performed on control or DDX1-knockdown SKOV3 and IG10 cells.
.001).
DDX1-knockdown IG10 cells expressing firefly luciferase were injected intra-
images of ovarian tumors.
roup). Error bar represents the mean ± SEM.
g syngeneic ovarian tumors derived from control and DDX1-knockdown IG10
ass in omentum (II), perihepatic area (III), mesentery (IV), lymph nodes (V), and
rihepatic, and other sites). Other sites include paraaortic lymph nodes, kidney,
d DDX-silenced tumors. Error bars represent the mean ± SD: *p < 0.05.
trol andDDX1-knockdown ovarian tumors. Scale bars, 30 mm. Relative levels of
cedures for IHC score; *p < 0.05). Error bars represent the mean ± SD. H&E,
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Figure 7. DDX1 Levels Are Positively Correlated with Clinical Outcome in Patients with Cancer
(A) Low levels of DDX1 are associated with poor overall survival in patients with ovarian tumors. Kaplan-Meyer plots for overall survival (OS) of patients with
ovarian serous adenocarcinoma (OV) are shown. The entire population (n = 388) was randomly split into training/validation cohorts (two-thirds and one-third), and
a correlation with the survival was determined as described in Supplemental Experimental Procedures. An analysis of the validation cohort (n = 129) is shown
here. RNASeq, RNA sequencing; pt, patients.
(B) Low levels of DDX1 are associated with poor overall survival in patients with kidney renal clear cell carcinoma (KIRC). An analysis of the validation cohort (n =
156) is shown here.
(C) Relative expression levels of miR-200a (p = 0.006) and miR-200c (p = 0.04) in the DDX1-low and -high groups from the validation cohort of ovarian serous
adenocarcinomas. Error bars represent the mean ± SD.
(D) Immunohistochemical analysis and in situ hybridization of DDX1 and miR-200a in human ovarian tumor tissue microarray. Scale bars, 100 mm.
See also Figure S7.
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Statistical Analysis
Differences between groups were analyzed using conventional Student’s t test
or ANOVA. Reported p values were two sided and considered significant at
<0.05. Statistical calculations were executed using GraphPad Prism 6.
ACCESSION NUMBERS
The GEO accession number for global miRNA PCR array data is GSE54990.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.07.058.
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